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Abstract
BACKGROUND
Mesenchymal stromal cell (MSC)-based therapy is currently under study to treat
inflammatory bowel diseases. MSC bioactive products could represent a valid
alternative to overcome issues associated with systemic whole-cell therapies.
However, MSC anti-inflammatory mechanisms differ between rodents and
humans, impairing the reliability of preclinical models.
AIM
To evaluate the effect of conditioned medium (CM) derived from porcine
vascular wall MSCs (pVW-MSCs) on survival and differentiation of porcine and
guinea pig enteric ganglia exposed to lipopolysaccharide (LPS).
METHODS
Primary cultures of enteric ganglia were obtained by mechanic and enzymatic
digestion of ileum resections from guinea pigs (Cavia porcellus) (GPEG) and pigs
(Suus scrofa) (PEG). pVW-MSCs were derived by enzymatic digestion from
vascular wall resections of porcine aorta and tested by immunoflowcytometry for
MSC immune profile. Enteric ganglia were treated with increasing concentrations
of LPS, CM derived by pVW-MSCs or a combination of CM and LPS 1 µg/mL.
Cell count and morphometric analysis of HuD positive neurons and glial
fibrillary acidic protein positive glial cells were performed by immunofluorecent
staining of cultured ganglia.
RESULTS
PEG showed a higher number of neurons compared to GPEG. Overall, CM
exerted a protective role on LPS-treated enteric ganglia. CM in combination with
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LPS increased the number of glial cells per ganglion in both cultures evoking glial
cells differentiation in porcine cultures.
CONCLUSION
These findings suggest an immunomodulating activity of pVW-MSCs mediators
on the enteric nervous system in inflammatory conditions.
Key words: Enteric nervous system; Mesenchymal stromal cells; Inflammatory bowel
disease; Ganglia; Translational models
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Core tip: Secretome of porcine vascular wall mesenchymal stromal cells (pVW-MSCs)
induced an increase of glial cell number in swine and guinea pig-derived enteric ganglia.
Co-treatment of enteric ganglia with lipopolysaccharide and conditioned medium
promoted glial cell differentiation only in pigs. These data indicate an immune activation
promoted by pVW-MSCs which could be more specific in higher mammals, suggesting
a careful consideration of the animal models used in research studies on cell-based
therapies.
Citation: Dothel G, Bernardini C, Zannoni A, Spirito MR, Salaroli R, Bacci ML, Forni M,
Ponti FD. Ex vivo effect of vascular wall stromal cells secretome on enteric ganglia. World J
Gastroenterol 2019; 25(33): 4892-4903
URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4892.htm
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INTRODUCTION
Inflammatory bowel diseases (IBDs), encompassing the two major forms Crohn’s
disease (CD) and ulcerative colitis (UC), are characterized by an overactive immune
response to unknown environmental triggers associated with specific genetic traits[1].
Genome-wide association studies advanced previous knowledge of genetic variants
associated with innate and adaptive immunity (e.g., NOD2, IL23R) revealing novel
pathophysiological mechanisms linked to autophagy and loss of epithelial barrier
function[2,3].  In  IBD,  chronic  intestinal  inflammation  induces  several  morpho-
functional changes of the enteric nervous system (ENS), including swallowing of
enteric nerve bundles and higher expression of several neurotransmitters[4].
Mesenchymal stromal cells  (MSCs) are currently under study as a therapeutic
option in regenerative medicine and as a novel treatment for autoimmune and chronic
inflammatory disorders including IBDs[5]. Although the mechanism underlying the
immunoregulatory  effect  of  MSCs  is  still  to  be  clarified,  their  role  in  balancing
immune homeostasis has been acknowledged[6]. Notably, pro- or anti-inflammatory
activity[7] along with other MSC biomolecules is settled by toll-like receptors 3 and 4,
the latter being one of the main sensors of bacterial lipopolysaccharide (LPS)[8,9].
MSCs respond to an inflammatory environment releasing CC chemokine ligand 2
and IL-10, which inhibits CD4 Th17 cells proliferation and IL-17 production[10] and
polarizes naïve T-cells to the regulatory Foxp3-positive phenotype (T-reg)[6]. These
pleiotropic,  anti-inflammatory  properties  justify  a  proof  of  concept  study  for  a
possible application of MSCs in IBDs, where Th-17 and Th-4/5 lymphocytes drive the
aberrant immune reaction of CD and UC, respectively. A phase III clinical trial of CD
with a systemic infusion of MSCs is currently ongoing[11], while local treatment of the
severe fistulizing form of CD was recently approved by EMA[12].
One  of  the  main  drawbacks  of  cell-based  therapy  regards  uncertainty  about
biodistribution and homing of cells to the target site of action. In particular, MSCs
tend to remain trapped in the microcirculation of pulmonary alveoli, allegedly for an
increased diameter acquired during in vitro expansion[13]. For these reasons, MSC-
derived  exosomes  as  well  as  MSC  secretome  are  gaining  attention  in  current
research[14-17]. Furthermore, a recent study showed that a vascular wall mesenchymal
stem  cells  isolated  by  porcine  aortic  tissue  (pVW-MSCs)  showed  mesenchymal
features[18] and the ability to differentiate in all the cellular components of a mature
vessel[19]. A deeper characterization demonstrated their metabolic properties[20] and
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their intrinsic attitude to promote angiogenesis also by paracrine action[21].
Interestingly, the key factor responsible for MSC anti-inflammatory action varies
among species and is related to a specific phylogenetic tree[22]. On this basis, this study
aims  at  investigating  a  possible  gap  between  rodent  and  swine  neuro-immune
response to MSC-derived bioactive products assuming pVW-MSC secretome as a
closer model from a translational point of view. To this purpose, we first compared
the effect of LPS on cell survival and differentiation in primary enteric ganglia derived
from guinea  pig  and pig  myenteric  plexus  (MP)  (GPEG and PEG,  respectively);
thereafter,  we  evaluated  the  effect  of  pVW-MSC secretome in  these  two ex-vivo
models of ENS.
MATERIALS AND METHODS
Animals
Animals were used after approval of the protocol by the local ethics committee and
following the guidelines of 3Rs implied in the EU directive 2010/63/EU for the use of
animal for experimental purposes and in accordance with the national legislation
(Decree 116/1992). In accordance with the 3Rs principle of Reduction[23] the animals
used in the present study served as controls in other experimental protocols carried
out in our facility.
Swine (Protocol number n.43-IX/9 all.37; 20/11/2012): Young commercial hybrids of
Sus  scrofa  (4  males–aged  4-5  wk,  7  ±  0.5  Kg  live  weight),  born  at  the  ASA Unit
(DIMEVET, University of Bologna), were enrolled in the study. Piglets were bred
under the lactating sow till 28 d, then weaned and kept in a multiple box for young
piglets, temperature was kept at 28 ± 1 °C with adequate ventilation and humidity in
relation to the young age. Surgical procedures were carried out during the morning in
the surgical  theatre  of  the DIMEVET facilities.  Animal  received an i.m.  bolus of
tiletamine-zolazepam (5 mg/kg) 10 min before induction; general anesthesia was
achieved using sevoflurane with an induction mask[24]. Animals were then sacrificed
with  a  single  bolus  (0.3  mL/kg)  of  Tanax  (embutramide/mebezonium
iodide/tetracaine hydrochloride;  Msd Animal Health Srl)  and the abdomen was
opened to remove the small intestine.
Guinea pigs (Protocol number 18/79/14): Male Dunkin-Hartley guinea pigs (Cavia
porcellus, 8 males–aged 3-5 wk, weight 200-280 g, Harlan Italy, Udine, IT) were kept in
home  cages  with  a  controlled  environment  (12  h  dark/light  cycle,  20-24  °C
temperature, 40%-70% humidity) with unlimited access to water and chow. The day
of the experiment, animals were sacrificed through isoflurane inhalation followed by
exsanguination through jugular excision. All the procedures were carried out in the
operating room of Medical and Surgical Department.
Isolation and culture of ganglia by pig and guinea pig myenteric plexus
Isolation of MP from 8 guinea pigs (3-5 wk) and 4 pigs (4-5 wk) was performed as
previously  described[25,26].  Briefly,  the  small  intestine  was  washed  with  sterile,
oxygenated Krebs solution containing (mM) NaCl 120.9, KCl 5, MgCl2 1.2, CaCl2 2.5,
glucose 11.5, NaHCO3 14.4, NaH2PO4 1.2 additioned with fungizone and penicillin-
streptomycin 10 ml/L (Sigma Aldrich-Merck, Darmstadt, Germany). MP was peeled
by 2-cm traits of small intestine cut in 1 mm × 1 mm fragments and digested in T25
plastic flasks with an enzymatic solution containing 1.25 mg/mL collagenase IV from
Clostridium histolyticum, 1 mg/mL dispase II from Bacillus polymyxa and 1 mg/mL
bovine serum albumin (Sigma Aldrich-Merck) in gentle agitation 30 min (guinea pig
tissues) or 45 min (pig tissues) at 37 °C. Reaction was stopped by placing flasks in ice
for 3 min. Digested tissues were washed with cold Krebs solution and collected in
DMEM.  Fragmented  neuronal  fibers  were  selected  over  muscle  bundles  with  a
stereomicroscope  (Nikon  C-PSCN  -  Nikon,  Tokyo,  Japan)  and  seeded  on
polyornithine-covered coverslips in 24-well plates with M199 medium enriched with
5% fetal bovine serum, 10 mL/L penicillin-streptomycin and 5% glucose (complete
M199-cM199). Plates were kept 24 h in a humidified chamber at 37 °C with 5% CO2.
Immune profiling and collection of media conditioned by porcine vascular wall
mesenchymal stromal cells
pVW-MSCs were isolated, characterized and maintained as previously described[27]. In
order to confirm the mesenchymal immunophenotype after cryopreservation, flow
cytometry analysis was performed before media collection. Briefly, 2 × 105 cells were
resuspended in 100 µL of phosphate buffered saline (PBS) and incubated for 1 h at 4
°C in the dark with appropriate fluorochrome-conjugated antibodies at the titers
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reported  in  Table  1.  Unstained  controls  to  evaluate  inherent  background  or
autofluorescence were obtained omitting primary antibodies. After incubation, cells
were washed twice and resuspended in 200 µl of PBS then analyzed with MacsQuant
Analyzer10 (Miltenyi Biotec, Bergisch Gladbach, Germany). For CD34 staining, after
the first incubation with the primary antibody, cells were washed and incubated with
PE-conjugated secondary antibody (Table 1) for 40 min at 4 °C in the dark. Data were
analyzed using the Flowlogic™ software (Miltenyi Biotec).
After  thawing  cellular  suspensions  were  plated  in  a  24-multi  well  plate  at  a
concentration  of  3  ×  104  cells/well  in  PGM  medium  (Promocell,  Heidelberg,
Germany), the day after, cells were washed with PBS and cultured for additional 24 h
in PGM, then media were collected, centrifuged at 800 × g for 10 min, filtered through
a 0.20-μm syringe filter, immediately frozen in liquid nitrogen and stored at -80 °C
until use.
Treatments
Enteric ganglia derived from each animal were seeded in 24 wells plates, a pool of 35
ganglia per well from 3 wells (triplicates) were considered for the analysis. After 2 d,
ganglia were incubated for 24 h with cM199 (CRTL) or one of the followings: cM199 +
0-0.1-1-10 µg/mL LPS (LPS from Escherichia coli O111:B4, Sigma Aldrich-Merck);
conditioned medium (CM) derived by culture flasks containing adherent pVW-MSCs
(10% in M199) or CM combined with LPS 1 µg/mL. Treatments were coded arbitrary
so that a second operator could carry on the operation blindly.
Immunocytochemistry analysis of enteric ganglia
At the end of 24-h treatment, cells were washed twice in cold PBS and fixed in 4%
paraformaldehyde for 1 h. After three washes with cold PBS, unspecific epitopes were
blocked by incubating fixed ganglia with a blocking solution of 0.5% Triton and
donkey serum 5% for 1 h. Ganglia were double-stained by overnight incubation at
4°C with a mix containing antibodies directed to the pan-neuronal marker HuD and
to the glial fibrillary acidic protein (GFAP). The following day, cells were washed
three  times  with  PBS  and  incubated  2  h  at  room temperature  with  appropriate
fluorescent anti-antibodies (Table 1). Negative controls included a pre-adsorption step
for 2 h with the specific blocking peptides in the preliminary tests and the omission of
the primary antibody in every run experiment. At the end of the procedure, coverslips
were mounted on slides with an anti-fade solution (10% Mowiol 4-88, Sigma Aldrich-
Merck)  containing 0.1  µg/mL DAPI.  Photomicrographs  of  single  ganglion were
obtained with a Zeiss Imager M1 microscope with dedicated software (AxioVision,
Carl Zeiss, Jena, Germany).
Imaging analysis of cultured ganglia
Cell count and morphometric analysis of photomicrographs were carried out blindly
with Image J software on the basis of a previously applied method[28]. Briefly, two axis
intersecting at a 90° angle were traced from the furthest ends of the cluster of cell
bodies. A first circle representing the core area was traced considering the intersection
of the two axis as the center and the longest axis as the diameter. Likewise, an outer
circle, having the same center as the former and the diameter extending to the furthest
fillopodium, was considered as the total area. The percentage of ganglion expansion
(Gang. Exp. %) on total area was calculated as follows: Gang.Exp.% = [(total area-core
area)]%100/(total area).
Statistical analysis
Results are reported as Tukey box-plots (middle lines-median values;  lower and
upper sides of the rectangles - 1st and 3rd percentile, whiskers - confidence intervals;
black dots - outliers). Statistical analysis was performed through GraphPad Prism
software  (GraphPad,  La  Jolla,  CA,  United  States)  on  data  retrieved  from  35
ganglia/well analyzed in triplicates for each experimental group. Normal distribution
was  confirmed  by  Shapiro-Wilk  test  and  Student  t  test  was  used  to  determine
statistical significance of the differences observed. Data significance was considered
when P < 0.05 or as reported in text.
RESULTS
Comparison of ganglia derived by pig and guinea pig myenteric plexa
After 2 d of culture in vitro, GPEG showed a more consistent morphology and cell
composition in comparison with PEG. GPEG showed a globular or bean-like shapes
with a core of cell bodies and glial cells radially protruding outward (Figure 1A).
Conversely, PEG were characterized by larger globular, bi- or tri-lobed shapes (Figure
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Table 1  Antibody reporting
Name Target Clonality Conjugation
Research
resource
identifiers
Species Supplier Catalognumber Application
Concentrati
onused
Anti-HuD Hu N-
terminus of
human HuD
Poly - AB_2101223 Gt Santa Cruz
Biotechnologi
es
sc-5977 IC 5 µg/mL
Anti-GFAP Hu Glial
Fibrillary
Acidic Protein
Mono - AB_10689630 Ms BD
Biosciences
561483 IC 1 µg/mL
Alexa 488 Gt IgM heavy
and light
chains
Poly Alexa Fluor®
488
AB_2535792 Dk Thermo
Fisher
Scientific
A-21206 IC 0.5 µg/mL
Alexa 555 Ms IgM
heavy and
light chains
Poly Alexa Fluor®
555
AB_2535853 Dk Thermo
Fisher
Scientific
A-21432 IC 0.5 µg/mL
Anti-CD 105 Hu CD105 (L-
isoform) cell
surface
antigen
Mono FITC AB_868768 Ms Abcam Ab53318 FC 2 µL/105
cells/100 µL
Anti-CD90 Hu
CD90/Thy-1
cell surface
antigen
Mono APC AB_10677422 Ms Abcam Ab139364 FC 1 µL/105
cells/100 µL
PE anti-
human
CD56
Hu CD56 cell
surface
antigen
Mono PE AB_314448 Ms Biolegend 304606 FC 2 µL/105
cells/100 µL
Human
CD44
antibody
Hu CD44
isoforms, 80-
95 Kd cell
surface
antigen
Mono PerCP AB_10645506 Rt Biolegend 103036 FC 0.5 µL/105
cells/100 µL
CD34
antibody
[EP373Y]
Hu CD34 cell
surface
antigen
Mono - AB_1640331 Rb Abcam Ab81289 FC 0.8 µL/105
cells/100 µL
Rabbit-PE Rb IgG heavy
and light
chains
Poly PE AB_10680576 Gt Abcam Ab97070 FC 0.5 µL/105
cells/100 µL
FITC: Fluorescein isothiocyanate; APC: Allophycocyanin; PE: Phycoerythrin; PerCP: Peridinin-chlorophyll-protein; Ms: Mouse; Rt: Rat; Gt: Goat; Dk:
Donkey; Hu: Human; GFAP: Glial fibrillary acidic protein IC: Immunocitochemistry; FC: Flowcitometry.
1E) with a number of total cells per ganglion about 4-fold higher when compared to
GPEG (213.7 ± 50.4/PEG vs 53.3 ± 5.2 cells/GPEG, P < 0.001, Figure 1B) and a higher
number of HuD-immunoreactive (HuD-IR) neurons per ganglion (+13.7%, Figure 1C).
Frequency analysis in Figure 1F and Figure 1G describes differences between GPEG
and PEG in terms of number of ganglia presenting 5 to 205 neurons. Moreover, PEG
showed  a  different  proportion  of  HuD-IR  neurons  and  GFAP-immunoreactive
(GFAP-IR)  glial  cells  (+12.7%,  P  <  0.05),  whereas  GPEG  presented  a  more
homogenous  distribution  of  both  cell  types.  Notably,  a  higher  number  of
neurons/ganglion (+12.7%, P < 0.05) and a lower number of glial cells/ganglion (-
15.7%, P < 0.05) were detected in PEG compared to GPEG (Figure 1D).
Effect of LPS on the number of cells in pig and guinea pig enteric ganglia
GPEG exposed to  increasing concentrations of  LPS displayed a  trend towards a
decreased number of neurons/ganglion, which was statistically significant only at the
concentration of 10 µg/ml (-22.3%, P < 0.05, Figure 2A). This effect was paralleled by
an increased number of glial cells/ganglion (+22.2%, P < 0.05, Figure 2A). Conversely,
no  effect  of  LPS  was  detected  on  cell  number  in  PEG  cultures  at  any  of  the
concentrations tested. Notably, the observed lower number of GFAP-IR glial cells
compared with HuD-IR neurons was similar in all the experimental groups (P < 0.05,
Figure 2B).
Characterization of pVW-MSCs phenotype
Flowcytometric analysis confirmed an unvaried immunophenotype of pVW-MSCs at
the third passage after cryopreservation, displaying MSC profile. In line with the
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Figure 1
Figure 1  Descriptive analysis of the morphology and cellular composition of guinea pig and pig enteric ganglia after 2 d in vitro. A and E: Representative
photomicrographs of guinea pig enteric ganglia (GPEG) and pig enteric ganglia (PEG) stained with HuD (red) and glial fibrillary acidic protein (GFAP) (green)
antibodies directed to neurons and glial cells respectively (scale bar: 100 µm); B: Total number of cells per ganglion in GPEG, left gray box plot, and PEG, right white
bars, cultures (53.3 ± 5.2 vs 213.7 ± 50.4 neurons per ganglion, bP < 0.001 vs GPEG); C: PEG showed a higher number of HuD-immunoreactive (HuD-IR) neurons
compared to GPEG (+13.7%, aP < 0.05); D: PEG and GPEG comparison of HuD-IR neurons and GFAP-immunoreactive (GFAP-IR) glial cells: PEG presented a
higher number of HuD-IR neurons compared to GFAP-IR glial cells (+28.4%, aP < 0.05). In comparison to GPEG, PEG showed a higher number of neurons (+12.7%,
cP < 0.05) and a lower number of GFAP-IR glial cells (-15.7%, fP < 0.01); B-D: Values reported as Tukey box-plots were obtained by three independent experiments.
F and G: Frequency analysis indicating the number of GPEG (F) and PEG (G) presenting 5 to 205 neurons. GPEG: Guinea pig enteric ganglia; PEG: Pig enteric
ganglia; GFAP: Glial fibrillary acidic protein; GFAP-IR: Glial fibrillary acidic protein-immunoreactive; HuD-IR: HuD-immunoreactive.
criteria for MSC characterization[18] more than 96% of the cell population analyzed was
positive for the markers of mesenchymal stemness, CD105, CD90, CD56, CD44, and
less than 2.5% was positive for the hematopoietic markers CD45 and CD34 (Figure 3).
Effect of pVW-MSCs mediators on GPEG and PEG exposed to LPS
Thereafter, we tested the effect of medium conditioned by pVW-MSCs (CM) on GPEG
and PEG cultured with LPS 1 µg/mL (LPS1).  The concentration of 1 µg/mL was
chosen  in  order  to  resemble  a  plausible  pathophysiological  condition  of  a  high
bacterial overload. Both guinea pig and pig cultures did not show any significant
change in the number of HuD+ neurons after treatments (Figure 4A and B, white
columns),  whereas glial  cell  number varied significantly (Figure 4A and B,  gray
columns). In particular, GPEG cultures showed a higher number of glial cells as a
result of co-treatment with CM+LPS1, compared to control and LPS1 groups (+13.9%,
P < 0.001; +16.5%, P < 0.01, respectively). As for PEG cultures an increased number of
GFAP+ glial cells was observed in CM group compared to control (+13.6%, P < 0.05)
and LPS1 groups (+20.2%, P < 0.05). In addition, number of glial cells was higher in
GPEG  treated  with  CM+LPS1  compared  to  LPS1  (+14.2%,  P  <  0.05).  The  main
interspecies difference was the variation of number of glial  cells  exposed to CM,
which increased in PEG but not in GPEG cultures compared to the relative control
(Figure 4A and B, third gray columns).
Morphometric  analysis  of  ganglia  upon treatment  with  pVW-MSC-conditioned
medium
As most of the observed differences regarded glial rather than neuronal cells, we
proceeded with a morphometric analysis of glial processes protruding outward the
ganglion center area measuring the extent of the ganglion expanded area (Gang.
Exp.%,  Figure  5A).  PEG  morphology  underwent  more  substantial  changes  in
comparison to GPEG cultures which did not show any significant change following
treatments showing a trend towards decreased Neur.Exp. (not statistically significant)
after LPS1 treatment compared to control and CM groups. Furthermore, CM+LPS1
induced a marked increase of Gang.Exp. which was approximately 2 fold higher
compared to both LPS1 and control groups (+43.2% vs CTRL, P < 0.01, Figure 5B).
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Figure 2
Figure 2  Effect of increasing concentration of lipopolysaccharide on enteric ganglia’ HUD+ neurons and
GFAP+ glial cells. A: In guinea pig-derived enteric ganglia - lipopolysaccharide (LPS) at 10 µg/mL decreased
number of HuD-immunoreactive (HuD-IR) neurons (left columns) and increased proliferation of glial fibrillary acidic
protein-immunoreactive (GFAP-IR) glial cells (right columns - HuD-IR neurons LPS10 vs CTRL, 22.3%, aP < 0.05;
GFAP-IR glial cells LPS10 vs CTRL, +22.2%, dP < 0.01); B: Conversely, in pig enteric ganglia the number of glial
cells at every LPS concentration tested did not change and was significatively lower compared to ganglionic neurons.
aP < 0.05. LPS: lipopolysaccharide; GFAP-IR: Glial fibrillary acidic protein-immunoreactive; HuD-IR: HuD-
immunoreactive.
DISCUSSION
The present study shows higher reactivity to MSC mediators of glial  cells  in pig
compared to guinea pig myenteric ganglia. In particular, we tested the effect of CM
derived by pVW-MSCs cultures on myenteric ganglia isolated from ileal tissue of
GPEG and PEG. These primary cultures exposed to LPS combined with pVW-MSCs
medium  showed  a  more  pronounced  proliferation  and  differentiation  in  PEG
compared  to  GPEG.  This  finding  suggests  a  different  and  higher  response  of
neuroimmune cells in higher mammals, which could impact on translational aspects
of current research on cell-based therapies.
In  the  present  study,  we  reported  interspecies  differences  in  the  cellular
composition of GPEG and PEG, with a higher neuronal/glial cells ratio in the latter,
which is in line with previous findings[29]. Furthermore, we described a slight decrease
in the number of neurons with a correspondent increase of glial cells as a result of
increasing micromolar concentrations of LPS in GPEG, but not in PEG. Finally, we
detected a marked modification of glial cell number and morphological modifications
of PEG in response to CM derived by pVW-MSCs cultures.
The higher number of neurons detected in PEG is in line with previous findings
describing an anatomical correlation in the size of myenteric ganglia and number of
cells per ganglion in large mammals[30]. Moreover, PEG size and number of cells were
more variable compared to GPEG, partially reflecting ganglia composition observed
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Figure 3
Figure 3  Flowcytometric analysis of cell-surface markers in porcine vascular wall mesenchymal stromal cells. Each graph shows the percentage of cells
expressing the specific marker reported [white area under the curve (AUC)] and the relative negative control (gray AUC, cells not incubated with any antibodies). This
analysis confirmed the mesenchymal stromal cell-like immune profile of porcine vascular wall mesenchymal stromal cells: CD105, CD90, CD56, CD44 were highly
expressed (> 96%) while the hematopoietic markers CD45 and CD43 were nearly absent (< 2.5%). AUC: Area under the curve.
in larger mammals, including humans[31]. Our findings show a low glial cells/neurons
ratio,  particularly in PEG, which is  in line with previous published data[29].  This
disproportion is easily filled within 48 h of culture, due to the rapid proliferation of
glial cells. In order to avoid a possible confounder, we chose a shorter time (24 h) to
limit the proliferation of glial cells, so as to detect small variations in number and
morphology of ganglia resulting after treatment.
Notably,  our  data  of  cell  count  analysis  correspond  to  micromolar  LPS
concentrations as a result of previous tests performed with nanomolar concentrations.
This analysis did not provide any measurable difference between groups (10-100 nM,
data not shown).  Moreover,  the scarce decrease of cell  number in GPEG and the
absence of any effect in PEG cultures even with LPS at the highest concentrations (10
µM)  reflects  a  remarkable  resilience  of  myenteric  neurons,  already  reported  in
previous works[32].  The slight decrease of neuronal cells at 10 µM of LPS in GPEG
could be ascribed to a lower sensitivity of guinea pigs to LPS compared to pigs, which
was  tested  in  previous  studies  on  LPS-induced  endotoxic  shock[33,34].  However,
Schuster  and  colleagues  described  a  counterintuitive  effect  of  LPS  promoting
neuronal viability and stemness in myenteric ganglia derived by MP of newborn
mice[32]. Differently from this work, our data did not show a higher neuron number as
a result of LPS treatment. Rather, most of the variations observed, as probably due to
age-related features  of  the  animals  used (young animals  rather  than newborns),
regarded glial cell number, which markedly varied upon treatment with pVW-MSCs
supernatants,  while  it  did  not  evoke  any  measurable  change  on  the  neuronal
component in either pig or guinea pig cultures. Indeed, CM derived by pVW-MSCs
alone or combined with 1 µg/mL LPS induced a higher number of glial cells in PEG,
while in GPEG-treated samples an akin effect was found only after the co-treatment,
suggesting a synergic activity of pVW-MSC-secreted molecules and LPS in promoting
glial  cells  mitosis  in  both  models.  This  observation  is  in  accordance  with  the
properties showed by brain vascular pericytes which favor glial cells’ phenotype,
being also spatially in close relation with this cell type in brain vessels[35,36]. Indeed,
pVW-MSCs,  along  with  a  MSC-like  immune  profile,  exhibited  an  intrinsic  pro-
angiogenic features in previous studies[19,27]. In addition, both LPS and MSCs promote
the activation of glial cells in brain-derived ganglia. In particular, a recent study in
vitro described the induction of glia proliferation induced by Wharton-jelly-derived
MSCs[37], while in vivo injection of LPS induced an overexpression of the glial marker
GFAP in brain tissue[38]. Interestingly, we observed a substantial variation of this cell
population in swine but not in guinea pig primary cultures. Allegedly, this might be
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Figure 4
Figure 4  Effect of porcine vascular wall mesenchymal stromal cells supernatants on the number of neurons
(left white bars) and glial cells (gray right bars) exposed to lipopolysaccharide 1 µg/mL. A: The number of
neurons in guinea pig enteric ganglia did not change significantly upon any of the treatment tested, whereas co-
treatment with conditioned medium (CM) and lipopolysaccharide 1 µg/mL (LPS1) (CM+LPS1) increased the number
of glial cells compared to control (CTRL) and LPS1-treated ganglia (+13.9%, bP < 0.001; +16.5%, dP < 0.01,
respectively); B: The number of neurons in pig enteric ganglia did not change as a result of any of the treatment
tested. Conversely glial cell number was higher in the CM group compared to control (+13.6%, aP < 0.05) and LPS1
(+20.2%, cP < 0.05). CM+LPS1 co-treatment increased the number of glial cells compared to LPS1-treated ganglia
(+14.2, eP < 0.05). LPS1: Lipopolysaccharide 1 µg/mL; CM: Conditioned medium. GFAP: Glial fibrillary acidic protein.
due to the species correspondence of porcine enteric glia with pVW-MSCs, which
would reflect the phylogenetic differences previously reported in signaling modalities
for MSC immunomodulation[39]. Indeed, in humans, non-human primates and pigs,
immunomodulation is  a  mechanism dependent  by indoleamine 2,3-dioxygenase
secretion whereas in rodents the same mechanism is associated with inducible nitric
oxide synthase expression and nitric oxide production[21,39].  Whether the observed
increase  in  number  and  shape  of  glial  cells  should  be  associated  with  a
compensative/therapeutic rather than a noxious stimulus  should be addressed by
further investigations on cytokine expression patterns. In this sense, an exhaustive
characterization  of  molecular  mechanisms  activated  by  MSC-derived  bioactive
molecules was beyond the scope of our analysis.
Taken together, these lines of evidence suggest an effect of pVW-MSCs mediators
on glial cells promoting neuronal remodeling and confirm the paramount role of this
cell  type  in  modulating  immune-mediated  changes  of  the  ENS.  A  further
characterization of the type of glial  cells involved in these changes is warranted.
Moreover, the observed interspecies differences should be taken into consideration in
future investigations of immune-mediated response to MSCs secretome in rodents
models.
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Figure 5
Figure 5  Effect of porcine vascular wall mesenchymal stromal cells supernatants on ganglion expansion. A: Representative photo of the morphometric
analysis performed to compare glial cells processes elongating from ganglion’s cores under different experimental conditions (scale bar: 100 µm); B: Relative area
occupied by glial processes of guinea pig (left, gray bars) and pig enteric ganglia (right white bars). Guinea pig enteric ganglia did not show any significant difference
between the different treatment groups. Conversely, pig enteric ganglia were more subjected to morphological changes: There was a decrease of the expanded area
in the group treated with lipopolysaccharide 1 µg/mL (LPS1) compared to control (-42.88%, aP < 0.05). Moreover, conditioned medium (CM) derived by porcine
vascular wall mesenchymal stromal cells evoked a higher protrusion of glial processes than LPS1 alone (+36.8%, cP < 0.05) which was remarkably higher in
combination with LPS1 (CM+LPS1, +43.2% vs CTRL, fP < 0.01; +60.9% vs LPS1, hP < 0.01). LPS1: Lipopolysaccharide 1 µg/mL; CM: Conditioned medium; GPEG:
Guinea pig enteric ganglia; PEG: Pig enteric ganglia.
ARTICLE HIGHLIGHTS
Research background
There is growing interest on mesenchymal stromal cells (MSC) as a novel therapeutic strategy to
treat auto-immune and inflammatory diseases. However, identifying optimal MSC sources and
limited reliability of current experimental models still represent a challenge in this field. Pigs
represent more closely human physiology and an accessible resource for ex vivo procedures.
Recently, our group isolated a population of pericytes from porcine aortic wall with an MSC
profile, currently cited as porcine vascular wall-MSC (pVW-MSC).
Research motivation
Inflammatory bowel diseases (IBDs), comprising the two major forms ulcerative colitis and
Crohn’s disease, are characterized by an aberrant immune response leading to severe damage of
the intestinal wall and functioning. Current trials are evaluating the application of cell-based
therapies  for  the  treatment  of  IBDs.  The  present  study describes  the  effect  of  pVW-MSC-
conditioned  medium  (CM)  on  enteric  ganglia  in  two  ex  vivo  models  of  IBDs  in  order  to
investigate a potential development of MSC-based treatment of IBDs.
Research objective
To  evaluate  the  effect  of  pVW-MSC  secretome  on  survival  and  differentiation  of  enteric
ganglionic  cells  isolated  by  guinea  pigs  (GPEG)  and  pigs  (PEG)  and  exposed  to
lipopolysaccharide (LPS).
Research methods
The expression of  standard MSC markers  in  pVW-MSC were  assessed by flow cytometry.
Increasing concentration of LPS were tested in both GPEG and PEG cultures. CM derived by
pVW-MSC cultures were added alone or in combination with 1µg of LPS in GPEG and PEG
cultures. Ganglionic cells were double-stained with antibodies directed to the pan-neuronal
marker, HuD and the glial fibrillary acidic protein, GFAP. Cell count and morphometric analysis
were performed to determine changes of neuronal and glial population.
Research results
Guinea-pig neurons and glial cells decreased and increased respectively in response to high
concentrations of LPS. These changes were not observed in pig primary cultures. pVW-MSC
secretome increased the number and differentiation of glial cells compared to neurons with a
more pronounced effect in PEG and in combination with LPS.
Research conclusions
These data showed a higher resilience of pig enteric ganglia to the main bacterial product LPS
compared  to  guinea  pig  and  a  higher  responsiveness  of  glial  cells  to  pVW-MSC secreted
mediators.
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Research perspectives
Neuro-immune changes induced by pVW-MSC represent an essential aspect in the development
of cell-based therapies. Further studies are warranted to investigate inter-species differences of
pVW-MSC secretome.
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